CN107233347A - A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application - Google Patents
A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application Download PDFInfo
- Publication number
- CN107233347A CN107233347A CN201710491372.2A CN201710491372A CN107233347A CN 107233347 A CN107233347 A CN 107233347A CN 201710491372 A CN201710491372 A CN 201710491372A CN 107233347 A CN107233347 A CN 107233347A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- alzheimer formula
- corynoline
- qingyanshengenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to a kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application;The pharmaceutical composition is formulated comprising following raw materials according:Corynoline, Qingyanshengenin, cyclovimbuxine D;With to treatment Alzheimer formula syndrome effect, substantially, Quality Control is stable, with low cost, Nantural non-toxic, and is suitable to the advantage of long-term taking.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition for treating Alzheimer formula syndrome and
It is applied.
Background technology
Alzheimer formula syndrome is a kind of continuation higher nerve functional activity obstacle, i.e., in the shape without the disturbance of consciousness
Under state, the obstacle in terms of memory, thinking, analysis judgement, visual space identification, mood.
Main principle of reatment includes:1. it is metabolized activating agent (ubiquinone with brain10, CDPC) and Brain circlulation accelerator
(hyderginum, flunarizine) activation brain metabolism, suppresses dull-witted development indirectly.Brain is metabolized activating agent mainly by promoting grape
Sugar absorbs, metabolism, and secondary expansion of cerebral vascular improves Nutrition and Metabolism, and Brain circlulation accelerator is the medicine of direct expansion of cerebral vascular;
2. the medicine of nerve transmission block is treated, such as amantadine can promote dopamine D_2 receptors, suppress its reuptake;Calcium hopantenate can promote
The intracerebral for entering glucose absorbs and is metabolized, serotonin concentration and cerebral blood flow (CBF) in increase brain tissue, hence it is evident that improve nervous symptoms;
Acetylcholine precursor medicine (lecithin, Choline Chloride) and cholinesterase inhibitor (eserine, tetrahydrochysene amido pyridine) are by increasing
Plus the function of acetylcholine system, improve nervous symptoms;Neuropeptide can improve the elderly's understanding, memory capability, mitigate depressed
With powerless symptom;3. symptomatic treatment, commonly uses the control Alzheimer formula syndrome such as Methotrexate, fluphenazinum, fluorine croak butanol and suffers from
Person's irritability and aggressive behavior;Conventional ritalin, chlorine ester acyl improve Alzheimer formula syndrome patients' depressive symptom;Conventional stabilize changes
Kind Alzheimer formula syndrome patients' anxiety symptom.
The content of the invention
It is an object of the invention to overcome defect of the prior art stable there is provided a special quality control, safely and effectively, natural nothing
A kind of pharmaceutical composition for treating Alzheimer formula syndrome of poison and its application.
The object of the present invention is achieved like this:The pharmaceutical composition is formulated comprising following raw materials according:Corynoline, Qingyang
Join aglycon, cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10~100 parts of corynoline, 10~100 parts of Qingyanshengenin, 7~100 parts of cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10~80 parts of corynoline, 10~80 parts of Qingyanshengenin, 7~80 parts of cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10~50 parts of corynoline, 10~50 parts of Qingyanshengenin, 7~50 parts of cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:20 parts of corynoline, 15 parts of Qingyanshengenin, 7 parts of cyclovimbuxine D.
Present invention also offers aforementioned pharmaceutical compositions in the pharmaceutical composition for preparing treatment Alzheimer formula syndrome
Application.
Heretofore described corynoline, Qingyanshengenin, cyclovimbuxine D can also may be used directly by being commercially available
To be obtained by plant extract.The present invention pulverizes and sieves above-mentioned raw materials respectively by weight, mixes, and loads capsule or compacting
For tablet;Or mixed with pharmaceutically acceptable carrier or diluent, it is reloaded into capsule or is compressed to tablet.
It is present invention also offers the instructions of taking of described pharmaceutical composition, its dose is in terms of said composition:Adult, 50
~100mg/ times, 3 times/day;Children, 20~50mg/kg times, 3 times/day, you can reach that treatment Alzheimer formula syndrome is faced
The effect of bed symptom, especially, the special population such as pregnant woman need to be followed the doctor's advice when taking, and its special adverse reaction is not yet found at present.
Treatment of the present invention means the treatment after morbidity, and the intervention of premorbid is not represented.
Heretofore described corynoline, molecular formula is C21H21NO5, molecular weight is 367.40, and molecular structural formula is:
Heretofore described Qingyanshengenin, molecular formula is C28H36NO8, molecular weight is 500.58, and molecular structural formula is:
Heretofore described cyclovimbuxine D, molecular formula is C26H46O, molecular weight is 402.67, and molecular structural formula is:
Found according to research, corynoline, Qingyanshengenin, the compound of cyclovimbuxine D composition can effectively suppress A Er
Hai Moshi syndrome rat nerve tissues morphological changes, improve cognition, the learning and memory of Alzheimer formula syndrome rat
Ability, hence it is evident that mitigate Alzheimer formula syndrome, therapeutic effect is better than ergometrine, CDPC, calcium hopantenate, gold
Firm alkanamine, lecithin.
Alzheimer formula syndrome can be effectively improved by keeping away dark experiment by rat step down test, rat and demonstrating the present invention
The cognition of rat, learning and remembering ability, therapeutic effect are better than ergometrine, CDPC, calcium hopantenate, amantadine, ovum
Phosphatide.
Found by om observation, the present invention can substantially suppress three layers of Alzheimer formula syndrome CA 1 of Hippocampus cone
Body cell arrangement disorder, cones's swelling, cell infiltration, proliferation of astrocytes, segmented cone cell body diminish
Or the extension of triangular in shape, apical dendrite, karyopycnosis and rupture, the thermophilic Yihong color of endochylema, matrix it is loose with micro- vacuolization, blood vessel around
The morphological change such as there is red blood cell to ooze out.
The present invention has to treatment Alzheimer formula syndrome effect substantially, and Quality Control is stable, with low cost, Nantural non-toxic,
And suitable for the advantage of long-term taking.
Brief description of the drawings
Fig. 1 is present invention influence (light morphologic on Alzheimer formula syndrome CA 1 of Hippocampus cortex cones
Mirror 0.8K ×) schematic diagram.
Embodiment
The present invention be a kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application, wherein, the drug regimen
Thing is formulated comprising following raw materials according:Corynoline, Qingyanshengenin, cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10~100 parts of corynoline, 10~100 parts of Qingyanshengenin, 7~100 parts of cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10~80 parts of corynoline, 10~80 parts of Qingyanshengenin, 7~80 parts of cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10~50 parts of corynoline, 10~50 parts of Qingyanshengenin, 7~50 parts of cyclovimbuxine D.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:20 parts of corynoline, 15 parts of Qingyanshengenin, 7 parts of cyclovimbuxine D.
Present invention also offers aforementioned pharmaceutical compositions in the pharmaceutical composition for preparing treatment Alzheimer formula syndrome
Application.
In order to more clearly explain the present invention, it is further described in conjunction with specific embodiment.It is specific real
Under applying for example:
Embodiment one
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:9 parts of corynoline, 101 parts of Qingyanshengenin, 6.5 parts of cyclovimbuxine D.
Embodiment two
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:102 parts of corynoline, 9 parts of Qingyanshengenin, 101 parts of cyclovimbuxine D.
Embodiment three
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:101 parts of corynoline, 102 parts of Qingyanshengenin, 6.3 parts of cyclovimbuxine D.
Example IV
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10 parts of corynoline, 10 parts of Qingyanshengenin, 7 parts of cyclovimbuxine D.
Embodiment five
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:100 parts of corynoline, 100 parts of Qingyanshengenin, 100 parts of cyclovimbuxine D.
Embodiment six
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:55 parts of corynoline, 55 parts of Qingyanshengenin, 53.5 parts of cyclovimbuxine D.
Embodiment seven
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:80 parts of corynoline, 80 parts of Qingyanshengenin, 80 parts of cyclovimbuxine D.
Embodiment eight
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:45 parts of corynoline, 45 parts of Qingyanshengenin, 43.5 parts of cyclovimbuxine D.
Embodiment nine
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:80 parts of corynoline, 10 parts of Qingyanshengenin, 55 parts of cyclovimbuxine D.
Embodiment ten
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:50 parts of corynoline, 50 parts of Qingyanshengenin, 50 parts of cyclovimbuxine D.
Embodiment 11
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:30 parts of corynoline, 30 parts of Qingyanshengenin, 28.5 parts of cyclovimbuxine D.
Embodiment 12
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:10 parts of corynoline, 50 parts of Qingyanshengenin, 18 parts of cyclovimbuxine D.
Embodiment 13
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated:20 parts of corynoline, 15 parts of Qingyanshengenin, 7 parts of cyclovimbuxine D.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and the not restriction to embodiment.
For the general technical staff of art, other various forms of changes can also be made on the basis of the above description
Or change.There is no necessity and possibility to exhaust all the enbodiments, and the obvious change thus amplified out
Or among changing still in the invention scope of the claims.
The present invention can be prepared into various various forms of medicaments by corynoline, Qingyanshengenin, cyclovimbuxine D, such as:
The forms such as aqueous solvent, powder and mixture;When needing to prepare aqueous solvent medicine is weighed according to following weight:Corynoline 20mg, green grass or young crops
Sun ginseng aglycon 30mg, cyclovimbuxine D 15mg, are dissolved in tri-distilled water, packing.When needing to prepare powder according to following heavy
Amount weighs medicine:Corynoline 20g, Qingyanshengenin 30g, cyclovimbuxine D 15g, mixing, packing.Closed when needing to prepare
During agent medicine is weighed according to following weight:Corynoline 20g, Qingyanshengenin 30g, cyclovimbuxine D 15g, packing, filling glue
Capsule.
Experimental example 1
Detection the present invention to rat diving tower, keep away the influence secretly tested;
1st, raw material:Corynoline, Qingyanshengenin, cyclovimbuxine D above-mentioned raw materials are by Shanghai Ke Xing commerce and trade Co., Ltd
Purchase;Hyderginum is purchased by Shanghai Hua Tai medicine companies limited company;CDPC is by Suzhou heavenly steed fine chemicals
Limited company purchases;Calcium hopantenate is purchased by Shanghai Jia Lun bio tech ltd;Amantadine is by Shijiazhuang City three
Purchased with pharmaceutcal corporation, Ltd;Lecithin is purchased by Guangzhou Bang Li bio tech ltd.
2nd, instrument:Rat diving tower record system is purchased by Huaibei Zhenghua Biological Instrument Co., Ltd., rat keeps away dark instrument
Purchased by Huaibei Zhenghua Biological Instrument Co., Ltd..
3rd, animal:Sprague-Dawley (SD) rat, 6 week old, male, 180~220g, cleaning grade are tested by Henan Province
Animal center is provided.
4th, experiment packet:(1) blank control group:Healthy SD rat 20, daily early morning empty stomach tri-distilled water gavage, gavage is held
Measure as 10ml/kg, continuous gavage 8 weeks;(2) Alzheimer formula syndromes models group:It is big that 2VO methods prepare Alzheimer formula syndrome
Mouse model 20;(3) of the present invention group of low dosage:Alzheimer formula syndromes models rat 20, daily early morning is sent out with this on an empty stomach
Bright solution gavage, gavage concentration 5mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks;(4) the middle dosage present invention
Group:Alzheimer formula syndromes models rat 20, daily early morning empty stomach solution gavage of the present invention, gavage concentration 10mg/kg,
Gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks;(5) of the present invention group of high dose:Alzheimer formula syndromes models rat
20, daily early morning uses solution gavage of the present invention on an empty stomach, and gavage concentration 20mg/kg, gavage capacity is administered for 10ml/kg, continuously
Gavage 8 weeks;(6) hyderginum group:Alzheimer formula syndromes models rat 20, daily early morning empty stomach hyderginum
Solution gavage, gavage concentration 2.0mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks;(7) CDPC group:
Alzheimer formula syndromes models rat 20, daily early morning uses CDPC solution gavage, gavage concentration 1.0mg/ on an empty stomach
Kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks;(8) calcium hopantenate group:Alzheimer formula syndromes models rat 20
Only, daily early morning uses calcium hopantenate solution gavage on an empty stomach, and gavage concentration 2mg/kg, gavage capacity is administered for 10ml/kg, continuous to fill
Stomach 8 weeks;(9) amantadine group:Alzheimer formula syndromes models rat 20, daily early morning is filled with amantadine solution on an empty stomach
Stomach, gavage concentration 0.5mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks;(10) lecithin group:Alzheimer formula
Syndromes models rat 20, daily early morning uses lecithin soln gavage, gavage concentration 0.2mg/kg on an empty stomach, and gavage capacity is
10ml/kg is administered, continuous gavage 8 weeks.
5th, experiment content:Rat step down test, rat keep away dark experiment.
6th, statistical method:All data are with mean ± standard deviationRepresent.Group difference compare with ANOVA and
Newman-Student Multiple range tests;T check analyses, are completed by the statistical softwares of SPSS 13.0, and bilateral P < 0.05 think difference
There is conspicuousness.
7th, result
Influence of 7.1 present invention to rat step down test:Result of the test shows that the present invention can significantly improve the examination of rat diving tower
Test incubation period, reduce errors number, and with significant dose dependent;With hyderginum, CDPC, homopantothenic acid
Calcium, amantadine, lecithin control group compare, and there is obvious difference (P < 0.05).(the results are shown in Table 1)
The present invention of table 1 can be to Alzheimer formula syndrome rat step down test influence
Note:Compared with Alzheimer formula syndromes models group, * P < 0.05;Of the present invention group is compared with high dose, # <
0.05。
7.2 present invention keep away the influence secretly tested to Alzheimer formula syndrome rat:Result of the test shows that the present invention can be bright
Aobvious raising Alzheimer formula syndrome rat keeps away dark experiment incubation period, reduces errors number, and with significant dose-dependant
Property;Compared with hyderginum, CDPC, calcium hopantenate, amantadine, lecithin control group, there is obvious difference
(P < 0.05).(the results are shown in Table 2)
The present invention of table 2 keeps away the influence secretly tested to Alzheimer formula syndrome rat
Note:Compared with Alzheimer formula syndromes models group, * P < 0.05;Of the present invention group is compared with high dose, # <
0.05。
Experimental example 2
The detection present invention is to CA 1 of Hippocampus cones's Morphology Effects.
1st, raw material:Corynoline, Qingyanshengenin, cyclovimbuxine D above-mentioned raw materials are by Shanghai Ke Xing commerce and trade Co., Ltd
Purchase.
2nd, instrument:TS1000 Nikon microscopes.
3rd, animal:SD rats, 6 week old, male, 180~220g, cleaning grade, are provided by experimental animal center of henan province.
4th, experiment packet:Packet:(1) Normal group:Healthy SD rat 20, daily early morning is filled with tri-distilled water on an empty stomach
Stomach, gavage capacity is 10ml/kg, continuous gavage 8 weeks;(2) Alzheimer formula syndromes models group:2VO methods prepare Alzheimer
Formula syndrome rat model 20;(3) of the present invention group is taken:Alzheimer formula syndromes models rat 20, daily early morning is empty
Abdomen solution gavage of the present invention, gavage concentration 10mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks;
5th, experiment content:Morphological observation under light microscopic.
6th, result:The present invention is on the morphologic influence of Alzheimer formula syndrome CA 1 of Hippocampus cortex cones
(light microscopic 0.8K ×).As shown in figure 1, the cones's arrangement of three layers of Alzheimer formula syndromes models group CA 1 of Hippocampus is disorderly
Disorderly;Segmented cone cellular swelling, and have cell infiltration, proliferation of astrocytes;Segmented cone cell body diminishes or is in
Triangle, apical dendrite extension has karyopycnosis and fracture phenomena, and endochylema is in uniform thermophilic Yihong color;Segmented cone cell nuclear shoals,
Matrix is loose with micro- vacuolization;There is red blood cell to ooze out around blood vessel, indivedual visible thin vessels hyperplasia.Taking of the present invention group can be bright
Aobvious to suppress hippocampus CA1 cones's morphological change, cellular morphology is normal, it is seen that typical three confluent monolayer cells arrangement.In Fig. 1
Shown blank control group is 1;Alzheimer formula syndromes models group is 2;It is 3 to take present invention group.
Heretofore described pharmaceutically acceptable carrier or the form of diluent and feature are by by mixed work
Property the amount of composition, method of administration, physiological disposition (including absorb, distribution, metabolism, excretion) and other known variable institute is really
It is fixed.Necessarily " acceptable ", i.e., they should can be adapted to these carriers with other compositions of preparation, not interfere with the effect of said preparation
Fruit and the recipient for being not detrimental to said preparation.For example, used pharmaceutical carriers can be solid or liquid.Solid is carried
The example of body is lactose, carclazyte, sucrose, talcum powder, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, poly-
Ethylene glycol, polyvinylpyrrolidone, collagen hydrolysate etc..The example of liquid-carrier be phosphate buffered saline solution, syrup,
Emulsion, wetting agent, sterile solution etc..Similarly, carrier or diluent may include time delay material well known in the art, such as individually
Glycerin monostearate or distearin or the mixture with wax.Large-scale medicament forms can be used.Therefore,
If using solid carrier, said preparation can be placed on hard gelatine capsule, into lozenge or sugar with piece agent, with powder or particle form
The form of ingot.The change of the amount of solid carrier will be very big, but preferably about 50mg to about 1g.When using liquid-carrier, preparation
Can be into syrup, emulsion, the form of soft gelatine capsule.
Claims (6)
1. a kind of pharmaceutical composition for treating Alzheimer formula syndrome, it is characterised in that:The pharmaceutical composition includes following original
Material is formulated:Corynoline, Qingyanshengenin, cyclovimbuxine D.
2. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that:The medicine
Compositions are formulated comprising following raw materials according according to parts by weight:10~100 parts of corynoline, 10~100 parts of Qingyanshengenin,
7~100 parts of cyclovimbuxine D.
3. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that:The medicine
Compositions are formulated comprising following raw materials according according to parts by weight:10~80 parts of corynoline, 10~80 parts of Qingyanshengenin, ring
7~80 parts of virobuxine D.
4. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that:The medicine
Compositions are formulated comprising following raw materials according according to parts by weight:10~50 parts of corynoline, 10~50 parts of Qingyanshengenin, ring
7~50 parts of virobuxine D.
5. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that:The medicine
Compositions are formulated comprising following raw materials according according to parts by weight:20 parts of corynoline, 15 parts of Qingyanshengenin, HuanweihuangyangxingD
7 parts of D.
6. a kind of pharmaceutical composition as described in claim any one of 1-5 is preparing the medicine for the treatment of Alzheimer formula syndrome
Application in composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710491372.2A CN107233347A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710491372.2A CN107233347A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107233347A true CN107233347A (en) | 2017-10-10 |
Family
ID=59986879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710491372.2A Pending CN107233347A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107233347A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113975284A (en) * | 2021-10-20 | 2022-01-28 | 暨南大学 | Pharmaceutical composition containing C21 steroid saponin and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104693265A (en) * | 2015-02-12 | 2015-06-10 | 赵全成 | Preparation method of cyclovirobuxine D and novel application of medicine |
CN104813159A (en) * | 2012-08-20 | 2015-07-29 | 高级科学研究委员会C.S.I.C. | Raman, infrared, or raman-infrared analysis of peripheral blood plasma protein structure and its relation to cognitive development in alzheimer's disease |
-
2017
- 2017-06-07 CN CN201710491372.2A patent/CN107233347A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104813159A (en) * | 2012-08-20 | 2015-07-29 | 高级科学研究委员会C.S.I.C. | Raman, infrared, or raman-infrared analysis of peripheral blood plasma protein structure and its relation to cognitive development in alzheimer's disease |
CN104693265A (en) * | 2015-02-12 | 2015-06-10 | 赵全成 | Preparation method of cyclovirobuxine D and novel application of medicine |
Non-Patent Citations (2)
Title |
---|
张士侠 等: "江苏地产白首乌C21 甾苷对D-半乳糖衰老模型小鼠的作用研究.", 《中国中药杂志》 * |
郭娜等: "耳叶牛皮消中C21甾类化学成分的分离与鉴定.", 《沈阳药科大学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113975284A (en) * | 2021-10-20 | 2022-01-28 | 暨南大学 | Pharmaceutical composition containing C21 steroid saponin and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102548571B (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
Barrett et al. | Assessing the risks and benefits of herbal medicine: an overview of scientific evidence | |
US20230201293A1 (en) | Application of a traditional chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumonia | |
CN107233347A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application | |
CN107233351A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application | |
CN107789349A (en) | Treat pharmaceutical composition and its application of Alzheimer syndrome | |
CN106860472A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application | |
CN102552107B (en) | Two-phase release preparation containing zolpidem or salt of zolpidem and preparation method thereof | |
CN106237268B (en) | It is a kind of to treat schizoid pharmaceutical composition and its application | |
CN106924226A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
CN103751207B (en) | The pharmaceutical composition for the treatment of Alzheimer formula syndrome and application thereof | |
CN104147146A (en) | Pharmaceutical composition capable of promoting excretion of lead, and preparation method and application thereof | |
CN107802634A (en) | A kind of pharmaceutical composition for treating Alzheimer syndrome and its application | |
CN107397751A (en) | Treat pharmaceutical composition and its application of Alzheimer formula syndrome | |
CN101199602B (en) | Containing medicament soft capsule for treating gynecology disease and preparing method thereof | |
CN107050005A (en) | A kind of pharmaceutical composition for treating atherosclerosis and its application | |
CN107802636A (en) | A kind of pharmaceutical composition for treating Alzheimer's disease and its application | |
CN106668037A (en) | Pharmaceutical composition for treating Alzheimer's syndrome and application | |
CN106667999A (en) | Pharmaceutical composition for treating Alzheimer's syndrome and application thereof | |
CN103751206A (en) | Medicinal composition for preventing Alzheimer's disease and application thereof | |
CN106667993A (en) | Pharmaceutical composition for treating Alzheimer's syndrome and application | |
CN103751205B (en) | The pharmaceutical composition for the treatment of vascular dementia and application thereof | |
CN107019684A (en) | Treat pharmaceutical composition and its application of craniocerebral injury caused by mental disorder | |
CN103751204B (en) | The pharmaceutical composition of prevention vascular dementia and application thereof | |
CN106822067A (en) | Treat the application of the pharmaceutical composition and the pharmaceutical composition of atherosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171010 |
|
WD01 | Invention patent application deemed withdrawn after publication |